sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. it was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. it has several adverse reactions on multi organ systems including hematologic system. although the neutropenia and thrombocytopenia commonly happens as gra...

introduction: imatinib mesylate is a selective inhibitor of tk and is considered now to be the frontline therapeutic agent during the chronic phase of cml. we have evaluated the efficacy of it on children with chronic-phase of cml. patients and methods: in a clinical trial study over the past 3 years, 14 patients (8 females and 6 males, 2.5-14 years old) were admitted with a diagnosis of cml. s...

fms-like tyrosine kinase-3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system. mutations of fms-like tyrosine kinase-3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lymphoblastic leukemia. the fms-like tyrosine kinase-3 muta...

it has been observed that lung cancer either non-small cell or small cell is responsible for eye metastases. this form of metastases in several cases was the first manifestation of the disease and further investigation led to the diagnosis of the underlying malignancy. both types of lung cancer are equally responsible for this demonstration. furthermore; both chemotherapy and tyrosine kinase in...

background and objective: gliomas are the most common primary brain tumors. despite therapeutic advances, the majority of gliomas do not respond to either chemo or radiotherapy. cd117, the gene product of c-kit has been expressed in cells of glial tumors. because gastrointestinal stromal tumors (gists) that express cd117 respond dramatically to treatment with tyrosine kinase inhibitors, identif...

   Background and Objective: Gliomas are the most common primary brain tumors. Despite therapeutic advances, the majority of gliomas do not respond to either chemo or radiotherapy. CD117, the gene product of c-kit has been expressed in cells of glial tumors. Because gastrointestinal stromal tumors (GISTs) that express CD117 respond dramatically to treatment with tyrosine kinase inhibitors, ide...

background & objectives: anaplastic lymphoma kinase (alk) is a receptor tyrosine kinase involved in the genesis of several human cancers. alk was initially identified because of its involvement in anaplastic large cell lymphoma (alcl). alk is believed to foster tumorigenesis following activation by autocrine and/or paracrine growth loops. studies reveal that the presence of anti-alk antibod...

background : fms-like tyrosine kinase 3 is a tyrosine kinase receptor that plays an important role in proliferation and differentiation of hematopoietic stem cells. internal tandem duplication and tyrosine kinase domain mutation are the two most common types of fms-like tyrosine kinase 3 mutations frequently reported in acute myeloid leukemia associated with pathogenesis of this disease. the pr...

expression of receptor tyrosine kinase ror1 in a wide variety of cancers has emerged as a new era focusing on targeting this receptor in cancer therapy. our preliminary re-sults indicate the presence of a truncated transcript of ror1 in tumor cells. the trun-cated ror1 encompasses extracellular and transmembrane domains, lacking catalytic kinase domain (ror1-ecd). as enzyme activity is highly d...